These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 26647070)
1. Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: In vitro and in vivo studies. Domin H; Przykaza Ł; Jantas D; Kozniewska E; Boguszewski PM; Śmiałowska M Neuropharmacology; 2016 Mar; 102():276-94. PubMed ID: 26647070 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of the group III mGlu receptor agonist ACPT-I after ischemic stroke in rats with essential hypertension. Domin H; Przykaza Ł; Kozniewska E; Boguszewski PM; Śmiałowska M Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):93-101. PubMed ID: 29438731 [TBL] [Abstract][Full Text] [Related]
3. Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo. Domin H; Gołembiowska K; Jantas D; Kamińska K; Zięba B; Smiałowska M Neurotox Res; 2014 Jul; 26(1):99-113. PubMed ID: 24402869 [TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of the allosteric agonist of metabotropic glutamate receptor 7 AMN082 on oxygen-glucose deprivation- and kainate-induced neuronal cell death. Domin H; Jantas D; Śmiałowska M Neurochem Int; 2015 Sep; 88():110-23. PubMed ID: 25576184 [TBL] [Abstract][Full Text] [Related]
6. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Kłak K; Pałucha A; Brański P; Sowa M; Pilc A Amino Acids; 2007 Feb; 32(2):169-72. PubMed ID: 16868652 [TBL] [Abstract][Full Text] [Related]
7. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Tatarczyńska E; Pałucha A; Szewczyk B; Chojnacka-Wójcik E; Wierońska J; Pilc A Pol J Pharmacol; 2002; 54(6):707-10. PubMed ID: 12866729 [TBL] [Abstract][Full Text] [Related]
8. The neuroprotective effects of orthosteric agonists of group II and III mGluRs in primary neuronal cell cultures are dependent on developmental stage. Jantas D; Gręda A; Gołda S; Korostyński M; Lasoń W Neuropharmacology; 2016 Dec; 111():195-211. PubMed ID: 27600687 [TBL] [Abstract][Full Text] [Related]
9. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Pałucha-Poniewiera A; Kłodzińska A; Stachowicz K; Tokarski K; Hess G; Schann S; Frauli M; Neuville P; Pilc A Neuropharmacology; 2008 Sep; 55(4):517-24. PubMed ID: 18619473 [TBL] [Abstract][Full Text] [Related]
10. Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala. Wierońska JM; Szewczyk B; Pałucha A; Brański P; Zieba B; Smiałowska M Pharmacol Rep; 2005; 57(6):734-43. PubMed ID: 16382191 [TBL] [Abstract][Full Text] [Related]
11. Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Stachowicz K; Chojnacka-Wójcik E; Kłak K; Pilc A Pharmacol Rep; 2006; 58(6):820-6. PubMed ID: 17220539 [TBL] [Abstract][Full Text] [Related]
12. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239 [TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y Y2 and Y5 receptors as promising targets for neuroprotection in primary neurons exposed to oxygen-glucose deprivation and in transient focal cerebral ischemia in rats. Domin H; Przykaza Ł; Jantas D; Kozniewska E; Boguszewski PM; Śmiałowska M Neuroscience; 2017 Mar; 344():305-325. PubMed ID: 28057538 [TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Stachowicz K; Chojnacka-Wójcik E; Kłak K; Pilc A Neuropharmacology; 2007 Feb; 52(2):306-12. PubMed ID: 17020774 [TBL] [Abstract][Full Text] [Related]
15. Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Uehara S; Muroyama A; Echigo N; Morimoto R; Otsuka M; Yatsushiro S; Moriyama Y Diabetes; 2004 Apr; 53(4):998-1006. PubMed ID: 15047615 [TBL] [Abstract][Full Text] [Related]
16. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Pałucha A; Tatarczyńska E; Brański P; Szewczyk B; Wierońska JM; Kłak K; Chojnacka-Wójcik E; Nowak G; Pilc A Neuropharmacology; 2004 Feb; 46(2):151-9. PubMed ID: 14680755 [TBL] [Abstract][Full Text] [Related]
17. Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord. Howson PA; Jane DE Br J Pharmacol; 2003 May; 139(1):147-55. PubMed ID: 12746233 [TBL] [Abstract][Full Text] [Related]
18. Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice. Pałucha-Poniewiera A; Novák K; Pilc A Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1454-7. PubMed ID: 19660510 [TBL] [Abstract][Full Text] [Related]
19. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634 [TBL] [Abstract][Full Text] [Related]
20. Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity. Lopez S; Jouve L; Turle-Lorenzo N; Kerkerian-Legoff L; Salin P; Amalric M Neurobiol Dis; 2012 Apr; 46(1):69-77. PubMed ID: 22245662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]